Here, we demonstrate for the first time that our proprietary novel retinamides can simultaneously inhibit both AR signaling and MNK facilitated eIF4E translation initiation and impede growth and progression of in androgen dependent (LNCaP) and castration resistant (C4-2B, 22Rv1) prostate cancer cells. The gene discussed is EIF4E; the disease is Familial prostate cancer.